内容紹介
Successful Treatment of Relapsed and Refractory Multiple Myeloma by Using Clarithromycin-Lenalidomide, Low-Dose Dexamethasone(BiRd), and Melphalan-Prednisolone(MP)
Summary
The development of novel agents has markedly improved the prognosis of multiple myeloma(MM). However, salvage therapies for patients with MM that is refractory to novel agents and conventional chemotherapies have not been established. Herein, we describe successful treatments for such patients with the combination of clarithromycin, lenalidomide, and low-dose dexamethasone(BiRd)with or without melphalan and prednisolone(MP). Although its duration was relatively short, the remission is important in terms of the salvage strategy until the second generation of novel agents becomes available.
要旨
われわれは,新規薬剤や化学療法に対して不応となった再発・難治性多発性骨髄腫に対して,clarithromycin,lenalidomide,low-dose dexamethasone(BiRd)療法とBiRd+melphalan,prednisolone(MP)療法の併用が有効であった3症例を経験した。これらの症例はいずれもlenalidomideに不応となっていたので,clarithromycinとmelphalanの併用がlenalidomideの治療抵抗性を解除することが示唆された。本治療は次世代新規薬登場までの有用なsalvage療法と考えられる。
目次
Summary
The development of novel agents has markedly improved the prognosis of multiple myeloma(MM). However, salvage therapies for patients with MM that is refractory to novel agents and conventional chemotherapies have not been established. Herein, we describe successful treatments for such patients with the combination of clarithromycin, lenalidomide, and low-dose dexamethasone(BiRd)with or without melphalan and prednisolone(MP). Although its duration was relatively short, the remission is important in terms of the salvage strategy until the second generation of novel agents becomes available.
要旨
われわれは,新規薬剤や化学療法に対して不応となった再発・難治性多発性骨髄腫に対して,clarithromycin,lenalidomide,low-dose dexamethasone(BiRd)療法とBiRd+melphalan,prednisolone(MP)療法の併用が有効であった3症例を経験した。これらの症例はいずれもlenalidomideに不応となっていたので,clarithromycinとmelphalanの併用がlenalidomideの治療抵抗性を解除することが示唆された。本治療は次世代新規薬登場までの有用なsalvage療法と考えられる。